66 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
of PATHFNDR-2 are incredibly exciting for both patients with acromegaly and the healthcare providers who treat them,” stated Monica R. Gadelha, M.D., Ph.D
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
8:03am
Exhibit 99.1 nd 42 Annual J.P. MORGAN Healthcare Conference JA NUA RY 9 , 2 02 4
Safe Harbor Statement This presentation contains forward-looking … of oral ~50 top option payers Branded Services HUB Third Party Specialty Healthcare Commercial Medicare Part D Pharmacies Practitioners 30.9% 57.9
8-K
iqc4d9 8g9c596u4w4
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
bhafjq3
11 Sep 23
Regulation FD Disclosure
6:05am
UPLOAD
qyb8td3gii7g
20 Dec 22
Letter from SEC
12:00am
8-K
EX-99.1
ecee5
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
m7cm7t27
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
424B5
wsiddfgo
13 Apr 22
Prospectus supplement for primary offering
4:22pm